{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:10:51Z","timestamp":1790611851444,"version":"4.1.0"},"reference-count":61,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T00:00:00Z","timestamp":1588723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.00823","type":"journal-article","created":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T02:26:25Z","timestamp":1588731985000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":81,"title":["HIVconsv Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02)"],"prefix":"10.3389","volume":"11","author":[{"given":"Beatriz","family":"Mothe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Ros\u00e1s-Umbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pep","family":"Coll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Manzardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C.","family":"Puertas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Mor\u00f3n-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuska","family":"Llano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samandhy","family":"Cede\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yovaninna","family":"Alarc\u00f3n-Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guadalupe G\u00f3mez","family":"Melis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Langohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana M.","family":"Barriocanal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Toro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Rovira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Carrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Meulbroek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Crook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund G.","family":"Wee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose M.","family":"Mir\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonaventura","family":"Clotet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Martinez-Picado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1\u0161","family":"Hanke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Brander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Molt\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The BCN02 Study Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,5,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/nm.4156","article-title":"Defective proviruses rapidly accumulate during acute HIV-1 infection","volume":"22","author":"Bruner","year":"2016","journal-title":"Nat Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"15109","DOI":"10.1073\/pnas.96.26.15109","article-title":"HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression","volume":"96","author":"Davey","year":"1999","journal-title":"Proc Natl Acad Sci USA."},{"key":"B3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/978-981-13-0484-2_2","article-title":"HIV T-cell vaccines","author":"Mothe","year":"2018","journal-title":"Advances in Experimental Medicine and Biology, Vol. 1075"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1097\/QAD.0b013e3282fdce94","article-title":"Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452)","volume":"22","author":"Autran","year":"2008","journal-title":"AIDS."},{"key":"B5","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1086\/655468","article-title":"AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1\u2013infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein","volume":"202","author":"Schooley","year":"2010","journal-title":"J Infect Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1016\/j.vaccine.2013.10.030","article-title":"Safety and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: a randomised placebo-controlled study","volume":"32","author":"Harrer","year":"2014","journal-title":"Vaccine."},{"key":"B7","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1086\/314895","article-title":"A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with Rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers","volume":"180","author":"Evans","year":"1999","journal-title":"J Infect Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"eaan8848","DOI":"10.1126\/scitranslmed.aan8848","article-title":"A randomized controlled safety\/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection","volume":"9","author":"Sneller","year":"2017","journal-title":"Sci Transl Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nm1461","article-title":"Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants","volume":"13","author":"Fischer","year":"2007","journal-title":"Nat Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"33987","DOI":"10.1038\/srep33987","article-title":"Epigraph: a vaccine design tool applied to an HIV therapeutic vaccine and a pan-filovirus vaccine","volume":"6","author":"Theiler","year":"2016","journal-title":"Sci Rep."},{"key":"B11","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12967-015-0392-5","article-title":"A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques","volume":"13","author":"Mothe","year":"2015","journal-title":"J Transl Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e984","DOI":"10.1371\/journal.pone.0000984","article-title":"Design and pre-clinical evaluation of a universal HIV-1 vaccine","volume":"2","author":"L\u00e9tourneau","year":"2007","journal-title":"PLoS ONE."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1371\/journal.ppat.0030157","article-title":"HIV-1 group M conserved elements vaccine","volume":"3","author":"Rolland","year":"2007","journal-title":"PLoS Pathog."},{"key":"B14","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/mt.2016.3","article-title":"Novel conserved-region T-cell mosaic vaccine with high global HIV-1 coverage is recognized by protective responses in untreated infection","volume":"24","author":"Ondondo","year":"2016","journal-title":"Mol Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1126\/science.aav5095","article-title":"Structural topology defines protective CD8 + T cell epitopes in the HIV proteome","volume":"364","author":"Gaiha","year":"2019","journal-title":"Science"},{"key":"B16","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/mt.2013.248","article-title":"Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1","volume":"22","author":"Borthwick","year":"2014","journal-title":"Mol Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e101591","DOI":"10.1371\/journal.pone.0101591","article-title":"Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial","volume":"9","author":"Hayton","year":"2014","journal-title":"PLoS ONE."},{"key":"B18","doi-asserted-by":"publisher","first-page":"16061","DOI":"10.1038\/mtm.2016.61","article-title":"Broad HIV-1 inhibition in vitro by vaccine-elicited CD8+ T cells in African adults","volume":"3","author":"Mutua","year":"2016","journal-title":"Mol Ther Methods Clin Dev."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7448\/IAS.20.1.21171","article-title":"Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects","volume":"20","author":"Hancock","year":"2017","journal-title":"J Int AIDS Soc."},{"key":"B20","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.eclinm.2019.05.009","article-title":"Therapeutic vaccination refocuses T-cell responses towards conserved regions of HIV-1 in early treated individuals (BCN 01 study)","volume":"11","author":"Mothe","year":"2019","journal-title":"Clin Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.3389\/fimmu.2018.03175","article-title":"A novel vaccine strategy employing serologically different chimpanzee adenoviral vectors for the prevention of HIV-1 and HCV coinfection","volume":"9","author":"Hartnell","year":"2018","journal-title":"Front Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e0197299","DOI":"10.1371\/journal.pone.0197299","article-title":"Randomized phase I trial HIV-CORE 003: depletion of serum amyloid P component and immunogenicity of DNA vaccination against HIV-1","volume":"13","author":"Borthwick","year":"2018","journal-title":"PLoS ONE."},{"key":"B23","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/S0140-6736(19)32990-3","article-title":"Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial","volume":"395","author":"Fidler","year":"2020","journal-title":"The Lancet"},{"key":"B24","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.immuni.2012.01.014","article-title":"Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation","volume":"36","author":"Shan","year":"2012","journal-title":"Immunity."},{"key":"B25","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.immuni.2018.04.030","article-title":"Targeting the latent reservoir for HIV-1","volume":"48","author":"Sengupta","year":"2018","journal-title":"Immunity."},{"key":"B26","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12981-017-0177-4","article-title":"Eradication of HIV-1 latent reservoirs through therapeutic vaccination","volume":"14","author":"Pankrac","year":"2017","journal-title":"AIDS Res Ther."},{"key":"B27","doi-asserted-by":"publisher","first-page":"993","DOI":"10.4161\/hv.23800","article-title":"Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation","volume":"9","author":"Rasmussen","year":"2013","journal-title":"Hum Vaccin Immunother."},{"key":"B28","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/nm.3489","article-title":"New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo","volume":"20","author":"Bullen","year":"2014","journal-title":"Nat Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1093\/jac\/dkt338","article-title":"Unique characteristics of histone deacetylase inhibitors in reactivation of latent HIV-1 in Bcl-2-transduced primary resting CD4+ T cells","volume":"69","author":"Shan","year":"2014","journal-title":"J Antimicrob Chemother."},{"key":"B30","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/nature11286","article-title":"Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy","volume":"487","author":"Archin","year":"2012","journal-title":"Nature."},{"key":"B31","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S0140-6736(05)67098-5","article-title":"Depletion of latent HIV-1 infection in vivo: a proof-of-concept study","volume":"366","author":"Lehrman","year":"2005","journal-title":"Lancet."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e1004071","DOI":"10.1371\/journal.ppat.1004071","article-title":"Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing","volume":"10","author":"Wei","year":"2014","journal-title":"PLoS Pathog."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e1005142","DOI":"10.1371\/journal.ppat.1005142","article-title":"The depsipeptide romidepsin reverses HIV-1 latency in vivo.","volume":"11","author":"S\u00f8gaard","year":"2015","journal-title":"PLoS Pathog."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e463","DOI":"10.1016\/S2352-3018(16)30055-8","article-title":"Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B\/2A trial","volume":"3","author":"Leth","year":"2016","journal-title":"Lancet HIV."},{"key":"B35","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1097\/QAD.0000000000002083","article-title":"Characterization of the HIV-1 transcription profile after romidepsin administration in ART-suppressed individuals","volume":"33","author":"Moron-Lopez","year":"2019","journal-title":"AIDS."},{"key":"B36","article-title":"Population pharmacokinetics of romidepsin as a latency reactivating agent in HIV-infected adults","volume-title":"18th International Workshop on Clinical Pharmacologyof Antiviral Therapy.","author":"Molt\u00f3","year":"2017"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e0175899","DOI":"10.1371\/journal.pone.0175899","article-title":"Sensitive quantification of the HIV-1 reservoir in gut-associated lymphoid tissue","volume":"12","author":"Mor\u00f3n-L\u00f3pez","year":"2017","journal-title":"PLoS ONE."},{"key":"B38","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/s41586-019-1027-4","article-title":"HIV-1 remission following CCR5\u039432\/\u039432 haematopoietic stem-cell transplantation","volume":"568","author":"Gupta","year":"2019","journal-title":"Nature."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e87334","DOI":"10.1371\/journal.pone.0087334","article-title":"Effect of maraviroc intensification on HIV-1-specific T cell immunity in recently HIV-1-infected individuals","volume":"9","author":"Kawana-Tachikawa","year":"2014","journal-title":"PLoS ONE."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e1003211","DOI":"10.1371\/journal.ppat.1003211","article-title":"Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI study","volume":"9","author":"S\u00e1ez-Ciri\u00f3n","year":"2013","journal-title":"PLoS Pathog."},{"key":"B41","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1093\/oxfordjournals.aje.a114212","article-title":"Binomial regression in GLIM: estimating risk ratios and risk differences","volume":"123","author":"Wacholder","year":"1986","journal-title":"Am J Epidemiol."},{"key":"B42","unstructured":"30628467R: A Language and Environment for Statistical Computing2017"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-08-1215","article-title":"Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma","volume":"15","author":"Woo","year":"2009","journal-title":"Clin Cancer Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.mcp.2005.09.008","article-title":"Effects of histone deacetylase inhibitor (HDACi) trichostatin-A (TSA) on the expression of housekeeping genes","volume":"20","author":"Mogal","year":"2006","journal-title":"Mol Cell Probes."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/nm1333","article-title":"AIDS restriction HLA allotypes target distinct intervals of HIV-1 pathogenesis","volume":"11","author":"Gao","year":"2005","journal-title":"Nat Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1146\/annurev.med.54.101601.152346","article-title":"The influence of HLA genotype on AIDS","volume":"54","author":"Carrington","year":"2003","journal-title":"Annu Rev Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1097\/COH.0000000000000316","article-title":"Lessons from acute HIV infection","volume":"11","author":"Robb","year":"2016","journal-title":"Curr Opin HIV AIDS."},{"key":"B48","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nature14053","article-title":"Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations","volume":"517","author":"Deng","year":"2015","journal-title":"Nature."},{"key":"B49","article-title":"Multidose IV romidepsin: no increased HIV-1 expression in persons on ART, ACTG A5315","volume-title":"Conference Retrovirus and Opportunistic Infections, March 4\u20137 2019, Seattle (#26)","author":"McMahon","year":"2019"},{"key":"B50","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1097\/QAD.0000000000000974","article-title":"HIV-1 transcriptional activity during frequent longitudinal sampling in aviremic patients on antiretroviral therapy","volume":"30","author":"Leth","year":"2016","journal-title":"AIDS."},{"key":"B51","doi-asserted-by":"publisher","first-page":"e520","DOI":"10.1016\/S2352-3018(15)00226-X","article-title":"Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study","volume":"2","author":"Elliott","year":"2015","journal-title":"Lancet HIV."},{"key":"B52","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/S2352-3018(14)70014-1","article-title":"Panobinostat, a histone deacetylase inhibitor, for latentvirus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1\/2, single group, clinical trial","volume":"1","author":"Rasmussen","year":"2014","journal-title":"Lancet HIV."},{"key":"B53","doi-asserted-by":"publisher","first-page":"3162","DOI":"10.3389\/fimmu.2018.03162","article-title":"Antigen production after latency reversal and expression of inhibitory receptors in CD8+ T cells limit the killing of HIV-1 reactivated cells","volume":"9","author":"Ruiz","year":"2019","journal-title":"Front Immunol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"e1004287","DOI":"10.1371\/journal.ppat.1004287","article-title":"Histone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-lymphocytes","volume":"10","author":"Jones","year":"2014","journal-title":"PLoS Pathog."},{"key":"B55","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1097\/01.aids.0000499516.66930.89","article-title":"The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption","volume":"30","author":"Li","year":"2016","journal-title":"AIDS."},{"key":"B56","doi-asserted-by":"publisher","first-page":"e03821","DOI":"10.7554\/eLife.03821","article-title":"HIV-1 DNA predicts disease progression and post-treatment virological control","volume":"3","author":"Williams","year":"2014","journal-title":"Elife."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1093\/infdis\/jiy479","article-title":"The control of HIV after antiretroviral medication pause (CHAMP) study: posttreatment controllers identified from 14 clinical studies","volume":"218","author":"Namazi","year":"2018","journal-title":"J Infect Dis."},{"key":"B58","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1038\/s41591-018-0026-6","article-title":"Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in fiebig I acute HIV infection","volume":"24","author":"Colby","year":"2018","journal-title":"Nat Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1093\/infdis\/jiz100","article-title":"Impact of treatment interruption on HIV reservoirs and lymphocyte subsets in individuals who initiated antiretroviral therapy during the early phase of infection","volume":"220","author":"Huiting","year":"2019","journal-title":"J Infect Dis."},{"key":"B60","doi-asserted-by":"publisher","first-page":"e259","DOI":"10.1016\/S2352-3018(19)30052-9","article-title":"Recommendations for analytical antiretroviral treatment interruptions in HIV research trials\u2014report of a consensus meeting","volume":"6","author":"Julg","year":"2019","journal-title":"Lancet HIV."},{"key":"B61","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1089\/aid.2014.0236","article-title":"Progress towards an HIV cure: update from the (2014). International AIDS society symposium","volume":"31","author":"Anderson","year":"2015","journal-title":"AIDS Res Hum Retroviruses."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00823\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T02:26:29Z","timestamp":1588731989000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00823\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,6]]},"references-count":61,"alternative-id":["10.3389\/fimmu.2020.00823"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.00823","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,6]]},"article-number":"823"}}